安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic . . . - PubMed
As B7-H3 (CD276) is expressed on central nervous system (CNS) tumors, we designed B7-H3-specific chimeric antigen receptor (CAR) T cells, confirmed their preclinical efficacy, and opened BrainChild-03 (NCT04185038), a first-in-human phase I trial administering repeated locoregional B7-H3 CAR T cells to children with recurrent refractory CNS
- Intracerebroventricular B7-H3-targeting CAR T cells for diffuse . . .
Next, we opened BrainChild-03 (NCT04185038), delivering B7-H3 CAR T cells to children with recurrent or refractory central nervous system (CNS) tumors and DIPG, and published on the
- CAR T cell therapies for diffuse midline glioma - Cell Press
In an open, single-site, Phase 1 clinical trial (BrainChild-03; NCT04185038) evaluating B7-H3 CAR T cells in DMG (among other CNS tumors), CAR T cells were administered ICV on a repeated, outpatient, every-other-week dosing regimen, and the first three treated patients received a total of 40 doses Evaluation of cytokines in serum and CSF
- Clinical Trial: NCT04185038 - My Cancer Genome
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt
- FDA Grants Breakthrough Therapy Designation for BrainChild . . . - BioSpace
This FDA designation was based on the promising overall survival benefit in patients with brain tumors treated with an autologous B7-H3 CAR T-cell therapy observed in the BrainChild-03 Phase 1 trial (NCT04185038), conducted by BrainChild Bio’s academic partner, Seattle Children’s, and recently published in Nature Medicine
- Abstract LB121: BrainChild-03: Intraventricular B7-H3 CAR T cells for . . .
Methods: A 3+3 statistical design was employed to assess the safety of repeated B7-H3 chimeric antigen receptor (CAR) T cells administered into the intracranial ventricular system (ICV) using an intrapatient dose escalation without lymphodepleting chemotherapy in pts 1-26 years of age with recurrent refractory CNS tumors including (non-pontine
- Glioma Clinical Trial - Study of B7-H3-Specific CAR T Cell Locoregional
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt
- CAR T cell therapies for diffuse midline glioma - ScienceDirect
In an open, single-site, Phase 1 clinical trial (BrainChild-03; NCT04185038) evaluating B7-H3 CAR T cells in DMG (among other CNS tumors), CAR T cells were administered ICV on a repeated, outpatient, every-other-week dosing regimen, and the first three treated patients received a total of 40 doses [43] Evaluation of cytokines in serum and CSF
|
|
|